Predictors of Interrupted Healthcare Coverage in a National Sample of US Refugees.

INTRODUCTION: Many refugees that resettled into the United States (US) arrive with psychological and physical distress. Their health needs are often met with inadequate healthcare. A variety of barriers negatively affect their healthcare access. Knowledge of demographic and social predictors related to key healthcare access components among refugees is limited. This study examines potential predictors of interrupted healthcare coverage-one key component of healthcare access-among refugees living in the US. METHODS: Using the 2016 Annual Survey of Refugees (ASR)nation-wide data collected from 4037 refugees, multiple logistic regression methods were utilized to identify socio-demographic predictors of interrupted healthcare coverage. Interrupted healthcare coverage was defined as one or more months in the past 12 months without coverage by Refugee Medical Assistance (RMA), Medicaid, or private health insurance. RESULTS: The following five socio-demographic factors were associated with a higher likelihood of interrupted healthcare coverage: Male gender, 20-49 years of age, lack of marriage, resettlement into the south or Midwest, and poor or no current English proficiency. Refugees with no job were less likely to have interrupted coverage compared to employed refugees. DISCUSSION: The increased likelihood of interrupted coverage among refugees with poor or no English proficiency supports the belief that limited English proficiency is a barrier to healthcare insurance enrollment. The increased likelihood of interrupted coverage for refugees resettled in the South is consistent with prior literature. In view of clear regional differences, further consideration of the effect of policy differences on refugees living in the US is worthwhile. The findings may help early refugee contacts risk stratify and more effectively allocate limited resources and assist policy makers as they amend and update programs linked to refugee healthcare access (e.g., RMA).

Sociodemographic Characteristics and Inadequate Usual Sources of Healthcare in a National Sample of US Refugees.

INTRODUCTION: Refugees resettled into the United States (US) face challenges in accessing adequate healthcare. Knowledge of demographic and social characteristics related to healthcare access among refugees is scarce. This study examines potential sociodemographic predictors of inadequate usual sources of care (USCs)-one key component of healthcare access-within the US refugee population. METHODS: The 2016 Annual Survey of Refugees (ASR) involving 4037 refugees resettled into the US served as the data source for this study. Inadequate USC was defined as a USC that was neither a private healthcare provider nor a health clinic. We used multiple binary logistic regression methods to identify sociodemographic predictors of inadequate USCs. In addition, we used multinomial logistic regression to further assess predictors of inadequate USCs with a particular focus on severely deficit USCs (i.e., emergency department dependence and USC absence). RESULTS: Refugees with interrupted healthcare coverage were more likely to have an inadequate USC. Refugees who were young (age 10-19), resettled into the western region of the US, and highly educated were less likely to have an inadequate USC. Refugees with an education level higher than secondary had a significantly lower likelihood of having a severely deficient USC, while refugees with interrupted healthcare were more than twice as likely to have a severely deficient USC. CONCLUSIONS: Considering these results alongside our previous healthcare coverage findings provides a more comprehensive understanding of sociodemographic predictors of poor healthcare access among refugees resettled into the US. This improved understanding has the potential to assist early refugee contacts toward more effective healthcare resource allocation and aid policymakers attempting to improve programs linked to refugee healthcare access.

Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.

Importance: The high and increasing expenditures for prescription medications in the US is a national problem. Objective: To explore the association of generic statin competition on relevant use and cost savings and to provide use and expenditure trends for all available statins for private and public payers and for out-of-pocket spending. Design, Setting, and Participants: This survey study evaluated data from the January 1, 2002, to December 31, 2018, Medical Expenditure Panel Survey by using a difference-in-differences analysis. Participants included noninstitutionalized individual statin users. Data were analyzed from November 1, 2020, to March 30, 2021. Exposures: The market entry of 5 generic statin medications (atorvastatin, rosuvastatin, simvastatin, lovastatin, and pravastatin). Main Outcomes and Measures: National- and individual-level reductions in the annual number of statin purchases and total expenditures across private insurance, public insurance (Medicaid and Medicare), and out-of-pocket spending (presented in 2018 US dollars). Results: Between January 1, 2002, and December 31, 2018, an average of 21.35 million statins (95% CI, 16.7-25.5 million) were purchased annually, with an average total annual cost of $24.5 billion (95% CI, $18.2-$28.8 billion). The number of brand-name statin purchases decreased by 90.9% (95% CI, 56%-98%) nationally and 27.4% (95% CI, 13%-40%) individually after the end of market exclusivity. Among major payers, the end of market exclusivity was associated with individual cost savings of $370.00 (95% CI, $430.70-$309.20) for private insurers, $281.00 (95% CI, $346.80-$215.30) for Medicare, $72.34 (95% CI, $95.22-$49.46) for Medicaid, and $211.90 (95% CI, $231.20-$192.50) for out-of-pocket spending. Combining all payers, the decrease translates to $925.60 (95% CI, $1005.00-$846.40) of annual savings per individual and $11.9 billion (95% CI, $10.9-$13.0 billion) for the US. Conclusions and Relevance: Results of this survey study suggest that full generic competition of statins was associated with significant cost savings across all major payers within the US health care system.